Abstract
CD155 is an immune checkpoint protein. Its overexpression is an indicator of poor prognosis in some types of cancer. However, the significance of CD155 expression in patients with triple-negative breast cancer, and the relationship between CD155 and programmed death-ligand 1 (PD-L1) expression, have not yet been analyzed in detail. Using immunohistochemical staining and tissue microarrays, we analyzed the expression profiles of CD155 and PD-L1 in 61 patients with triple-negative breast cancer. Relapse-free survival and overall survival rates were compared according to CD155 expression. The correlation between CD155 expression and clinicopathological factors, including PD-L1 expression (using SP142 and 73-10 assays), was also examined. CD155 expression was noted in 25 patients (41.0%) in this cohort. CD155 expression did not correlate with pathological stage, histological grade, Ki-67 labeling index, or stromal tumor-infiltrating lymphocytes. Only PD-L1 expression in tumor cells by SP142 assay significantly correlated with CD155 expression (p = 0.035); however, PD-L1 expression in tumor cells by 73-10 assay did not show a correlation (p = 0.115). Using the 73-10 assay, 59% of patients showed CD155 and/or PD-L1 expression in tumo...Continue Reading
References
Nov 1, 1991·Histopathology·C W Elston, I O Ellis
Mar 10, 1989·Cell·C L MendelsohnV R Racaniello
Jul 17, 2001·Gut·D MassonM G Denis
Mar 3, 2007·The Lancet Oncology·Susan CleatorR Charles Coombes
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca DentSteven A Narod
Mar 25, 2010·Cancer Science·Reiko NakaiYoshitake Hayashi
Oct 3, 2012·Journal of Cell Science·Yoshiyuki RikitakeYoshimi Takai
Sep 13, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R SalgadoUNKNOWN International TILs Working Group 2014
May 4, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rita NandaLaurence Buisseret
Jun 18, 2017·Cancer Immunology, Immunotherapy : CII·Feng XuYuwen Zhu
Sep 6, 2017·Virus Research·Jonathan R BowersKatherine J D A Excoffon
Sep 9, 2017·Cancer Research·Weiling HeZunfu Ke
Dec 14, 2017·The Lancet Oncology·Carsten DenkertSibylle Loibl
Mar 24, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott GettingerJulie Brahmer
Jul 25, 2018·Apoptosis : an International Journal on Programmed Cell Death·Jian GaoChenghai Zhao
Oct 3, 2018·Cellular & Molecular Immunology·Paola Kučan BrlićStipan Jonjić
Oct 23, 2018·The New England Journal of Medicine·Peter SchmidUNKNOWN IMpassion130 Trial Investigators
Nov 16, 2018·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Tomohito SaitoTomohiro Murakawa
Apr 30, 2019·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Hongmei YongWei Zhao
Jun 10, 2019·Life Sciences·Hana TrikiBoutheina Cherif
Jul 26, 2019·JAMA Oncology·Suzanne L TopalianMario Sznol
Sep 29, 2019·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Nicola L LawsonCraig Barker
Nov 5, 2019·Frontiers in Oncology·Qiang WuQinghua Zhou
Dec 13, 2019·Clinical and Experimental Immunology·H Harjunpää, C Guillerey
Feb 6, 2020·International Journal of Molecular Sciences·Rosa MolfettaRossella Paolini
Oct 29, 2020·Cancer Immunology, Immunotherapy : CII·Koji TeramotoYataro Daigo
Nov 18, 2020·PloS One·Katsuhiro YoshikawaTomoharu Sugie
Mar 8, 2021·BMC Cancer·Katsuhiro YoshikawaTomoharu Sugie